Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye
07/11/2007 23:06
PR Newswire
SYDNEY, November 7 /PRNewswire/ -- In the Lancet, on Tuesday November, 6th new results of the
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 2007 clinical
trial have been published and presented on the same date at a press
conference held during the AHA.
- First lipid modifying agent shown to reduce the need for treatment of
the leading causes of blindness and deteriorating vision in patients with
type 2 diabetes
- Reduces need for laser treatment in patients with and without known
diabetic retinopathy
- Significantly decreases progression of diabetic eye disease
If you are interested in knowing more about this breaking news
and in getting additional information on the management of microvascular
complications in type 2 diabetes, we are pleased to invite you to visit "the
Field Study Investigators Website", where you will have the opportunity to
login to the Webcast of the press conference.
Please click below: http://www.thefieldtrial.org
Media Contact: Beth Quinlivan, University of Sydney, Ph: +61-2-9036-6528, Mob: +61-0-419-229-134, bquinlivan@med.usyd.edu.au